Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47,770 matching trials from the live ClinicalTrials.gov search.
Conditions
Cancer, Physical Activity
Interventions
Intervention
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 39 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Winston-Salem, North Carolina
Conditions
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Anemia, Refractory Multiple Myeloma, Secondary Acute Myeloid Leukemia, Secondary Myelofibrosis, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Waldenstrom Macroglobulinemia
Interventions
deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

A Hybrid Effectiveness-Implementation Trial of Group CBT in Urban Schools

NCT02651402
Conditions
Anxiety Disorders
Interventions
FRIENDS for Life, Adapted FRIENDS, Train-the-Trainer, Train-the-Trainer Plus
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 99 Years
Enrollment
495 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 4 Interventional Results available

Optimal Blood Pressure Treatment Thresholds Postpartum

NCT06069102
Conditions
Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Hypertension, Eclampsia, Gestational Hypertension, Cardiovascular Diseases, Toxemia, Pregnancy Complications, Vascular Diseases, Hypertension, Pregnancy Induced, Hypertension;Pre-Eclamptic
Interventions
Usual care, Tight blood pressure control
Drug
Lead sponsor
Alisse Hauspurg
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions
Creating Health Online Course, Delayed access to Creating Health Online Course
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Human Papillomavirus
Interventions
Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Results available

Evaluation of the AMICUS RBCx System in Sickle Cell Patients

NCT02372877
Conditions
Sickle Cell Anemia
Interventions
Amicus Red Cell Exchange in SCD patients
Device
Lead sponsor
Fenwal, Inc.
Industry
Eligibility
6 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • Detroit, Michigan • St Louis, Missouri + 3 more
Conditions
Artificial Intelligence
Interventions
Complexity score and implementation
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Weight-Loss in African American Cancer Survivors in the Deep South

NCT03150381
Conditions
Weight Loss, Cancer
Interventions
Weight Loss Only, Weight Loss Plus, Control
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Liraglutide Pen Injector, Saline Injections
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Depressive Disorder, Major
Interventions
No Intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more
Conditions
Sedentary Behavior, Insulin Sensitivity, Sedentary Lifestyle
Interventions
SIT, ACTIVE, EX
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Completed Phase 2 Interventional Results available

Role of Exenatide in Type 1 Diabetes

NCT00456300
Conditions
Type 1 Diabetes
Interventions
Exenatide, Insulin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Mother and Child Health Outcomes After Maternal Bariatric Surgery

NCT03297307
Conditions
Weight Loss
Interventions
Presurgical Counseling
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
HIV, Medication Adherence, Telemedicine
Interventions
Face-to-Face ART Adherence Intervention, Carium Mobile Health Platform
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • Providence, Rhode Island
Conditions
Treatment Adherence
Interventions
Food Assistance Program, Standard of Care
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Richmond, Virginia
Completed Not applicable Interventional Accepts healthy volunteers

Melanoma Risk Assessment & Tailored Intervention

NCT01356771
Conditions
Melanoma, Skin Cancer
Interventions
Surveys & Mailed Materials
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Wound Debridement
Interventions
HemCon Dressings and HemCon ChitoGauze; chitosan-based., Gauze and saline dressings.
Device
Lead sponsor
HemCon Medical Technologies, Inc
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Female, Gynecologic Cancer
Interventions
Acupuncture
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Hatha Yoga on Mental Health

NCT05777044
Conditions
Depression, Anxiety, Mental Health Issue
Interventions
Yoga
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Auburn, Alabama
Conditions
Dysphagia, Parkinson Disease
Interventions
Aria Sensor
Device
Lead sponsor
Northwestern University
Other
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Evanston, Illinois
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial

NCT07282444
Conditions
Lung Carcinoma, Head and Neck Carcinoma
Interventions
Training and Education, Communication Intervention, Survey Administration, Interview, Electronic Health Record Review
Behavioral · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Substance Use Disorders, Parent-Child Relations, Parent Child Abuse
Interventions
MIO-CPP, MIO-CPP-CRS
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Esophageal Neoplasm, Esophageal Polyp, Endoscopic Submucosal Dissection, Bipolar Electocautery
Interventions
Endoscopic Submucosal Dissection, Bipolar electrocautery knife
Procedure · Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas